CVC Capital Partners, a private equity firm, completed the acquisition of a majority stake in Genetic Group, a pharma CDMO business which focuses on the development and supply of products into the respiratory, ophthalmic and oncology therapeutic areas, for £254m. "The Strategic Opportunities platform invests in high-quality businesses with longer growth horizons, and the investment in Genetic fits perfectly within this strategy, especially with the partnership with the Pavese family. We look forward to supporting collaboration between Genetic and our existing portfolio company DFE Pharma, and leveraging CVC's broader global network," Michael Lavrysen, CVC Senior Managing Director.